Cyprus Health and Social Sciences University, Faculty of Medicine, Department of Medical Microbiology, Güzelyurt, Cyprus.
Cyprus Health and Social Sciences University, Faculty of Medicine, Department of Immunology, Güzelyurt, Cyprus.
J Infect Dev Ctries. 2023 Feb 28;17(2):178-181. doi: 10.3855/jidc.16842.
A vaccine against coronavirus disease 2019 (COVID-19) is critically needed for older adults because of the increased morbidity and mortality rates.
In this prospective study, we analysed the titre magnitude of the IgG antibodies directed against the SARS-CoV-2 Spike Protein S1 (S1-RBD) antigen in both CoronaVac and Pfizer-BioNTech groups. The samples were tested to detect antibodies that bind to the receptor-binding domain of the spike protein of SARS-CoV-2 using the Enzyme-Linked Immunosorbent Assay (ELISA) technique with SARS-CoV-2 IgG II Quant. The cut-off value was > 50 AU/mL. GraphPad Prism software was used. Statistical significance was defined at p < 0.05.
The CoronaVac group (12 females, 13 males) had a mean age of 69.64 ± 1.38 years. The Pfizer-BioNTech group (13 males, 12 females) had a mean age of 72.36 ± 1.44 years. The anti- S1-RBD titre decrease rate from the 1st to the 3rd month for CoronaVac and Pfizer-BioNTech groups was 74.31% and 86.48%, respectively. There was no statistically significant difference in the antibody titre between the 1st month and 3rd month for the CoronaVac group. However, there was a significant difference between the 1st and 3rd month in the Pfizer-BioNTech group. In addition, there was no statistically significant difference in the genders between the 1st and 3rd month of the antibody titres for both the CoronaVac Pfizer-BioNTech group.
The levels of anti-S1-RBD, the preliminary outcome data of our study, represents one piece of the puzzle of humoral response and duration of vaccination protection.
由于发病率和死亡率的增加，急需为老年人开发针对 2019 年冠状病毒病（COVID-19）的疫苗。
在这项前瞻性研究中，我们分析了科兴和国药集团疫苗组中针对 SARS-CoV-2 刺突蛋白 S1（S1-RBD）抗原的 IgG 抗体效价。使用 ELISA 技术（使用 SARS-CoV-2 IgG II Quant 检测）测试样本，以检测与 SARS-CoV-2 刺突蛋白受体结合域结合的抗体。截断值>50 AU/mL。使用 GraphPad Prism 软件。定义 p<0.05 为具有统计学意义。
科兴组（12 名女性，13 名男性）的平均年龄为 69.64±1.38 岁。辉瑞组（13 名男性，12 名女性）的平均年龄为 72.36±1.44 岁。科兴和国药集团疫苗组从第 1 个月到第 3 个月，抗 S1-RBD 效价下降率分别为 74.31%和 86.48%。科兴组第 1 个月和第 3 个月的抗体滴度没有统计学差异。然而，辉瑞组第 1 个月和第 3 个月之间有显著差异。此外，在第 1 个月和第 3 个月的抗体滴度方面，男女之间在科兴和国药集团疫苗组中均无统计学差异。
抗 S1-RBD 水平是体液反应和疫苗保护持续时间的初步结果数据之一。
